AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1606114 — intervention group
Group type: COMPARATOR
Intervention: Two catheters introduced in different directions into different pockets of amniotic fluid
Number of subjects: 20
Study 3987798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of cefuroxime (250 mg) in patients with peritonitis
Number of subjects: 19
Study 3987798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of cefuroxime (250 mg) in patients with peritonitis
Number of subjects: 19
Study 3987798 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of cefuroxime (250 mg) in uninfected patients
Number of subjects: 19
Study 3987798 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal administration of cefuroxime (250 mg) in uninfected patients
Number of subjects: 19
Study 31560945 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (10 sessions at 2 mA to the right and left DLPFC)
Number of subjects: 40
Study 31560945 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (10 sessions)
Number of subjects: 40
Study 29330176 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided physical exercise and dietary therapy programme (PED‐t)
Number of subjects: 10
Study 25662447 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 120
Study 25662447 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 120
Study 25377395 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and 0.15 mg/kg ketamine (group 1)
Number of subjects: 60
Study 25377395 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and 0.3 mg/kg ketamine (group 2)
Number of subjects: 60
Study 25377395 — intervention group
Group type: COMPARATOR
Intervention: Morphine and normal saline placebo (standard care group)
Number of subjects: 60
Study 23718080 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% procaine solution administered via electrophoresis and mesotherapy
Number of subjects: 95
Study 23718080 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered via galvanization and mesotherapy
Number of subjects: 95
Study 20964768 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block
Number of subjects: 41
Study 20964768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ilioinguinal block
Number of subjects: 41
Study 18226669 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch
Number of subjects: 104
Study 18226669 — intervention group
Group type: COMPARATOR
Intervention: Monophasic combination oral contraceptive (COC)
Number of subjects: 104
Study 18226669 — intervention group
Group type: COMPARATOR
Intervention: Triphasic COC
Number of subjects: 104
Study 16620305 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (120 microg/day) for 4 weeks
Number of subjects: 25
Study 16620305 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 25
Study 12729137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlatex condom
Number of subjects: 830
Study 12729137 — intervention group
Group type: COMPARATOR
Intervention: Latex condom
Number of subjects: 830
Study 11103375 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 0
Study 11103375 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 0
Study 11103375 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 9180855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 30 mg/day for 5 years
Number of subjects: 494
Study 9180855 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 494
Study 1286499 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.89 mg IV, range: 0.4 mg to 1 mg)
Number of subjects: 184
Study 1286499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 1286499 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 184
Study 3812947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular nalbuphine 20 mg
Number of subjects: 80
Study 3812947 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine 100 mg
Number of subjects: 80
Study 3812947 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of mothers given nalbuphine
Number of subjects: 80
Study 3812947 — intervention group
Group type: COMPARATOR
Intervention: Infants of mothers given pethidine
Number of subjects: 80
Study 28950158 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic gymnastic exercise (15 minutes per session, at least three times a week for three months)
Number of subjects: 140
Study 28950158 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic gymnastic exercise
Number of subjects: 140
Study 28950158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic gymnastic exercise)
Number of subjects: 140
Study 26446253 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly
Number of subjects: 89
Study 26446253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 25703411 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT with sNAG (poly-N-acetyl glucosamine nanofibers)
Number of subjects: 20
Study 25703411 — intervention group
Group type: COMPARATOR
Intervention: NPWT alone
Number of subjects: 20
Study 25703411 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT with sNAG in patients treated with antiplatelet drugs
Number of subjects: 20
Study 23735352 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg administered intravenously twice)
Number of subjects: 520
Study 23735352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg administered intravenously twice)
Number of subjects: 520
Study 23735352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 20663805 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 20663805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18283083 — intervention group
Group type: EXPERIMENTAL
Intervention: Better informing patients of the uses of records for medical research purposes
Number of subjects: 0
Study 18283083 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent procedures that explain the nature of the research and the uses of the data
Number of subjects: 0
Study 18283083 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of identifiers, such as social security numbers for central follow-up
Number of subjects: 0
Study 18283083 — intervention group
Group type: EXPERIMENTAL
Intervention: Legislative changes to reduce restrictions on data use
Number of subjects: 0
Study 16174205 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT group supervision
Number of subjects: 9
Study 16174205 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of psychiatric registrars
Number of subjects: 9
Study 12854928 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 238
Study 12854928 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 238
Study 12854928 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia, Spinal anesthesia, Combined spinal-epidural
Number of subjects: 238
Study 11021273 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary artery (IMA) graft
Number of subjects: 137
Study 11021273 — intervention group
Group type: COMPARATOR
Intervention: Vein graft surgery
Number of subjects: 137
Study 8712143 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg every morning)
Number of subjects: 30
Study 8712143 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-sustained release (90 to 180 mg twice daily)
Number of subjects: 30
Study 1940058 — intervention group
Group type: COMPARATOR
Intervention: AZT 0.5 g/day p.o.
Number of subjects: 30
Study 1940058 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT 0.5 g/day p.o. plus IVIG 0.4 g/kg for three consecutive days, followed by 0.6 g/kg every fourth week
Number of subjects: 30
Study 1940058 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT 0.5 g/day p.o. and IVIG
Number of subjects: 30
Study 1940058 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT 0.5 g/day p.o. plus IVIG
Number of subjects: 30
Study 7036400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 8
Study 7036400 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo capsules
Number of subjects: 8
Study 7036400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8
Study 31683226 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured and individualised education program delivered by a primary care nurse, consisting of six face-to-face sessions of 30 minutes each, with follow-ups after 12 and 24 months.
Number of subjects: 236
Study 31683226 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured and individualised education program delivered by a primary care nurse.
Number of subjects: 236
Study 31683226 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 236
Study 31479137 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 2862
Study 31479137 — intervention group
Group type: COMPARATOR
Intervention: Medical masks
Number of subjects: 2862
Study 28526315 — intervention group
Group type: EXPERIMENTAL
Intervention: VAP education (intensive educational program)
Number of subjects: 102
Study 28526315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VAP education)
Number of subjects: 102
Study 25361552 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental MVP
Number of subjects: 3679
Study 25361552 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental NDMs
Number of subjects: 3679
Study 23831502 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with task cards integrating pictures and written instructions close together
Number of subjects: 111
Study 23831502 — intervention group
Group type: COMPARATOR
Intervention: Control group with written instructions placed under the picture on the task cards
Number of subjects: 111
Study 21733742 — intervention group
Group type: EXPERIMENTAL
Intervention: Groningen Ultra Low Resistance (GULR)
Number of subjects: 80
Study 21733742 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox2
Number of subjects: 80
Study 21733742 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 19398814 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance spectroscopy method applied to effective electrical properties of cancellous bone
Number of subjects: 0
Study 19398814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis with normally distributed random noise added to data
Number of subjects: 0
Study 16393881 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer CAG repeats in second polymorphic KCNN3 region
Number of subjects: 101
Study 16393881 — intervention group
Group type: COMPARATOR
Intervention: Control group (46 individuals)
Number of subjects: 101
Study 15296683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored lifestyle self-management intervention including follow-up telephone calls
Number of subjects: 100
Study 15296683 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 100
Study 11506106 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (2, 4, and 6% end tidal; n = 10)
Number of subjects: 20
Study 11506106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1, 2, and 3% end tidal; n = 10)
Number of subjects: 20
Study 9205768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 400 mg and ranitidine 300 mg combined with amoxicillin 750 mg and metronidazole 500 mg for 14 days
Number of subjects: 30
Study 9205768 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the same treatment
Number of subjects: 30
Study 7786219 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy surgery with long‐acting gas
Number of subjects: 0
Study 7786219 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy surgery with silicone oil
Number of subjects: 0
Study 7786219 — intervention group
Group type: COMPARATOR
Intervention: Preoperative aphakia or pseudophakia
Number of subjects: 0
Study 7786219 — intervention group
Group type: COMPARATOR
Intervention: Preoperative iris neovascularization
Number of subjects: 0
Study 7786219 — intervention group
Group type: COMPARATOR
Intervention: Reoperation
Number of subjects: 0
Study 7786219 — intervention group
Group type: COMPARATOR
Intervention: Absence of a fluid/gas exchange
Number of subjects: 0
Study 7786219 — intervention group
Group type: COMPARATOR
Intervention: Corneal touch by silicone oil
Number of subjects: 0
Study 7786219 — intervention group
Group type: COMPARATOR
Intervention: Presence of aqueous cells
Number of subjects: 0
Study 7786219 — intervention group
Group type: COMPARATOR
Intervention: Presence of aqueous flare
Number of subjects: 0
Study 7786219 — intervention group
Group type: COMPARATOR
Intervention: Corneal abnormalities
Number of subjects: 0
Study 2223334 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg‐1
Number of subjects: 28
Study 2223334 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 28
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 716
Study 638961 — intervention group
Group type: COMPARATOR
Intervention: Extended radical mastectomy
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N- (negative axillary nodes)
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ (positive axillary nodes)
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ 1-3 nodes
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ greater than 3 nodes
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N- IMN+ (internal mammary nodes positive)
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ IMN+ (internal mammary nodes positive)
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N-
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N- IMN+
Number of subjects: 716
Study 638961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy, N+ IMN+
Number of subjects: 716
Study 31731089 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 230
Study 31731089 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT added to RIETE score
Number of subjects: 230
Study 31731089 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT log-unit increase
Number of subjects: 230
Study 31731089 — intervention group
Group type: COMPARATOR
Intervention: RIETE score
Number of subjects: 230
Study 31148473 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Daily Sweepstakes
Number of subjects: 805
Study 31148473 — intervention group
Group type: EXPERIMENTAL
Intervention: Deadline Sweepstakes
Number of subjects: 805
Study 31148473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweepstakes Plus Deposit Contract
Number of subjects: 805
Study 31148473 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless-enabled pill bottle and daily reminder messages
Number of subjects: 805
Study 28602435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage bursectomy
Number of subjects: 164
Study 28602435 — intervention group
Group type: COMPARATOR
Intervention: 2-stage bursectomy
Number of subjects: 164
Study 26418007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast volume group (0.75 ml/kg)
Number of subjects: 34
Study 26418007 — intervention group
Group type: COMPARATOR
Intervention: Routine contrast volume group (1.5 ml/kg)
Number of subjects: 34
Study 24638015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin plus cisplatin (AP)
Number of subjects: 284
Study 24638015 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan plus cisplatin (IP)
Number of subjects: 284
Study 21239131 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral enteral contrast (water)
Number of subjects: 40
Study 21239131 — intervention group
Group type: COMPARATOR
Intervention: Positive enteral contrast (2% water soluble iodinated contrast)
Number of subjects: 40
Study 20646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative strategy with antibiotics: hospital admission, supportive measures, and at least 48 hours of intravenous antibiotics switched to oral for a total duration of 10 days.
Number of subjects: 533
Study 20646266 — intervention group
Group type: COMPARATOR
Intervention: Liberal strategy without antibiotics: admission only if needed on clinical grounds, supportive measures only.
Number of subjects: 533
Study 20646266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies (antibiotics and no antibiotics)
Number of subjects: 533
Study 17205556 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered stiffness shoes
Number of subjects: 14
Study 17205556 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered angle shoes
Number of subjects: 14
Study 17205556 — intervention group
Group type: COMPARATOR
Intervention: Placebo shoe
Number of subjects: 14
Study 15919269 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural (EPI)
Number of subjects: 91
Study 15919269 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve catheter plus patient-controlled analgesia (ICN-PCA)
Number of subjects: 91
Study 15919269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 12411537 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (1 g (kg body mass)(-1) glucose 75 min prior to exercise)
Number of subjects: 8
Study 12411537 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 8
Study 9283064 — intervention group
Group type: COMPARATOR
Intervention: Mibefradil 50 mg
Number of subjects: 307
Study 9283064 — intervention group
Group type: COMPARATOR
Intervention: Mibefradil 100 mg
Number of subjects: 307
Study 9283064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 8437701 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 18
Study 8437701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8437701 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight into psychogenic mechanisms
Number of subjects: 18
Study 2940607 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,500‐Hz sine‐wave electrical stimulation modulated at 50 bursts per second to the gastrocnemius muscle
Number of subjects: 14
Study 2940607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 14
Study 30111065 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoqinglong decoction combined with noninvasive ventilation
Number of subjects: 84
Study 30111065 — intervention group
Group type: COMPARATOR
Intervention: Western medicine combined with noninvasive ventilator therapy (Control group)
Number of subjects: 84
Study 27311495 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (5 μg/h, titrated to a maximum of 40 μg/h)
Number of subjects: 186
Study 27311495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 24833354 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP plus siltuximab (11 mg/kg every 3 weeks)
Number of subjects: 106
Study 24833354 — intervention group
Group type: COMPARATOR
Intervention: VMP
Number of subjects: 106
Study 24833354 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP plus siltuximab (S+VMP)
Number of subjects: 106
Study 22452610 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH training load
Number of subjects: 7
Study 22452610 — intervention group
Group type: COMPARATOR
Intervention: LOW training load
Number of subjects: 7
Study 20505271 — intervention group
Group type: EXPERIMENTAL
Intervention: HTLV-1 infection
Number of subjects: 0
Study 20505271 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent studies on CD4 T cells
Number of subjects: 0
Study 17594199 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX (7 patients)
Number of subjects: 23
Study 17594199 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine plus TMP-SMX (5 patients)
Number of subjects: 23
Study 17594199 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither drug (5 patients)
Number of subjects: 23
Study 17594199 — intervention group
Group type: COMPARATOR
Intervention: Combination group (zidovudine plus TMP-SMX)
Number of subjects: 23
Study 17594199 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX
Number of subjects: 23
Study 16249848 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm (SEPRA+)
Number of subjects: 62
Study 16249848 — intervention group
Group type: COMPARATOR
Intervention: No Seprafilm (SEPRA‐)
Number of subjects: 62
Study 12401599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg, maximum 4 mg (Group 1)
Number of subjects: 149
Study 12401599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 0.5 mg/kg, maximum 25 mg (Group 2)
Number of subjects: 149
Study 12401599 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (Group 3)
Number of subjects: 149
Study 10023504 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg i.v. clomipramine
Number of subjects: 50
Study 10023504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10023504 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week oral clomipramine
Number of subjects: 50
Study 10023504 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week oral fluvoxamine
Number of subjects: 50
Study 7587726 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ patients
Number of subjects: 0
Study 7587726 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 1955308 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg yohimbine per os 4 times a day for 3 weeks
Number of subjects: 20